

CITRUS RESEARCH AND DEVELOPMENT FOUNDATION, INC.

Commercial Product Delivery Committee

Meeting Minutes

January 21, 2014

A meeting of the Commercial Product Delivery Committee of the Citrus Research and Development Foundation, Inc. was held on Tuesday, January 21, 2014 at the Ben Hill Griffin Citrus Hall, Lake Alfred, Florida. The meeting was properly noticed and recorded. The meeting was called to order at 9:35 am by Chairman Ben McLean. Roll was called and a quorum was present. Committee members participating were: Dr. Tim Anglea; Mr. David Howard; Mr. Ricke Kress; Mr. Peter McClure; Mr. Ben McLean; Mr. Jerry Newlin; Mr. Andy Rackley (phone); Mr. Tom Stopyra and Mr. Hugh Thompson. Committee members not in attendance were: Mr. Joe L. Davis, Jr.; Dr. Mary Duryea and Ms. Shannon Shepp. Also participating were: Mr. Larry Black; Mr. Dan Botts; Dr. Harold Browning; Dr. Jim Dukowitz; Ms. Diane Johnson; Ms. Audrey Nowicki; Dr. Jim Syvertsen; and Dr. Tom Turpen.

Mr. Kress moved to accept the minutes of the December 10, 2013 meeting. The motion was seconded by Mr. Newlin and passed unanimously.

The proposed allocation of funds for large-scale mating disruption of citrus leafminer for validation and product launch was discussed. ISCA Technologies, Inc. is requesting \$400,000 funding from CRDF with an additional \$240,000 to be provided by growers. Terms of the funding agreement were discussed and options were considered. Mr. Newlin made a motion to recommend an equal share investment by ISCA, cooperating growers and CRDF. The alternative involving a royalty return should be pursued if the first recommendation is not realized. The motion was seconded by Mr. McClure and passed unanimously.

A Research Services Agreement involving Dr. Gonzalez from University of Florida was proposed to conduct *in vitro* testing of antimicrobial compounds on citrus leaves for efficacy against HLB. The plan for 60 tests over a six month period has a budget of \$266,025 at a per test cost of \$4,433.75. Dr. Anglea made a motion to request Board approval of the agreement as proposed and not to exceed \$266,025. The motion was seconded by Mr. Stopyra and passed unanimously.

Dr. Browning reported that the Executive Committee met earlier this month and approved the scope of services for Dr. Syvertsen to serve as a consultant to manage field trials. Dr. Browning is working with IFAS to develop a trial administrator position to assure these field trials are conducted as planned and on time. Funding for this function has already been approved.

Dr. Dukowitz and Dr. Turpen conducted a review of the current CPD projects, including Antibacterial Compounds, Natural Occurring Microbial Products, Area Wide Insect Management, Tolerant Rootstock Plantings, and Thermal Therapy. Dr. Turpen presented a new project idea to the committee, terming it psyllid shield. This idea is based on RNAi targeted to ACP delivered by the CTV vector. The concept builds off of the nuPsyllid project and the InnoCentive™ program. This is targeted to protect young plantings by

killing ACP which feed on these plants. Mr. Newlin made a motion to add psyllid shield to project Tier 1. The motion was seconded by Mr. Howard and passed unanimously.

Two plant growth regulator field trials were approved at the December CPD meeting. Two additional trials were presented again to the committee with additional information. The first addresses frequent, low rate, applications of 2,4-D and other options to encourage plant health response. This would be a 14-month study starting February 2014 at six sites (Valencias and Hamlins) at a cost of \$64,230. Mr. Newlin made a motion to recommend Board approval of this trial. The motion was seconded by Mr. Stopyra and passed unanimously. The additional trial was deferred for discussion at a later meeting, since it doesn't start until fall of 2014.

Two additional plant growth regulator trials were presented for consideration. These Valencia trials would be conducted by Dr. Albrigo of UF. The first trial would include 2,4-D plus AVG treatments at a cost of \$39,795. The other trial proposes 2,4-D, 1-MCP, S-ABA and Jasmonic Acid treatments at a cost of \$12,734. Mr. Newlin made a motion to recommend Board approval of Dr. Albrigo's two additional trials at a cost of \$52,529. The motion was seconded by Mr. Stopyra and passed unanimously.

Dr. Dukowitz recommended moving the Mature Citrus Tissue Facility (MCTF) from Tier 1-Active Projects to Tier 2-Facilitate and Monitoring, and recommended moving the general RNAi project from Tier 2 to the Tier 3-Information only. Mr. Kress made a motion to adopt the new tier structure as discussed. The motion was seconded by Mr. Thompson and passed unanimously.

The Diaprepes pheromone project was discussed, and USDA is ready to move forward with licensing. The committee supported Dr. Dukowitz and Dr. Turpen's continued pursuit if it doesn't involve a large time commitment.

Other Business: There was no new business to discuss.

With no further business, the meeting was adjourned at 12:58 pm

Minutes submitted by Diane Johnson